Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

Babak Sayad; Fatemeh Norooznezhad; Alireza Farokhi

首页> 外文期刊>Hepatitis Monthly >Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

【24h】

Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

机译：关于“ Sofosbuvir，Daclatasvir和利巴韦林12周治疗1型和3型肝炎丙型肝炎患者的疗效”的评论

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatitis Monthly》 |2017年第3期|共页
作者
Babak Sayad; Fatemeh Norooznezhad; Alireza Farokhi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3 [J] . Shahin Merat, Amir Houshang Sharifi, Arghavan Haj-Sheykholeslami, Hepatitis Monthly . 2017,第1期

机译：索非布韦，达卡他韦和利巴韦林治疗12周基因型1和3的丙型肝炎患者的疗效12周
2. Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long-term clinical outcomes. [J] . Mazzarelli Chiara, Childs Kate, Montague Sarah, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：基因型3丙型肝炎和肝硬化患者的Sofosbuvir和Daclatasvir的体重基础利用素12周：疗效分析和长期临床结果。
3. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy [J] . Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, The European journal of health economics: HEPAC : health economics in prevention and care . 2018,第1期

机译：Daclatasvir + Sofosbuvir +利巴韦林（16周和12周）使用的成本效益分析与Sofosbuvir +利巴韦林（16周和24周）治疗意大利丙型肝炎病毒基因型3的肝硬化患者治疗
4. High Prevalence of Fatigue and Depression in HIV/Hepatitis C Co-infected Patients Treated with Pegylated Interferon/ Ribavirin [C] . K. Jones, A. Talal, S. Ferrando International AIDS Conference . 2004

机译：用聚乙二醇化干扰素/利巴韦林治疗的艾滋病毒/丙型肝炎COR感染患者疲劳和抑郁症高患病率
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir Ledipasvir and Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis [O] . William Stokes, Carol Fenton, Fiona Clement, 2017

机译：Sofosbuvir和Ledipasvir对比SofosbuvirLedipasvir和Ribavirin治疗慢性丙型肝炎肝硬化且治疗失败的患者12周的疗效和安全性：系统评价和荟萃分析
7. Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3” [O] . Babak Sayad, Fatemeh Norooznezhad, Alireza Farokhi 2017

机译：评论“Sofosbuvir，Daclatasvir和利巴韦林在治疗肝硬化患者的肝硬化，基因型1和3”中的疗效评论

Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

著录项

相似文献

相关主题

期刊订阅